Methods of Treating and Preventing Angioedema and Vascular Leakage

Novel mechanism of action to block the vasicular permeability that is induced by the attack phase plasma in C1 inhibitor (C1-INH) deficient patients. Background: Angioedemia associated with C1-INH deficiency is an inherited or acquired condition that affects 20 percent of the population. The condition can be disfiguring, painful and sometimes fatal. Existing treatments primarily replace or enhance the production of C1-INH, but these options are limited to availability, price, side effects, and long term risks. New therapeutic modalities that address these issues are sorely needed. Technology Overview: Dr. Berhane Ghebrehiwet, D.V.M., D.Sc., Professor of Medicine and Pathology at Sony Brook University, has identified proprietary peptides and antibodies that are being used in a novel mechanism of action to block the vascular permeability that is induced by the attack phase of plasma in the C1-INH deficient AE patients. This mechanism of action relates to blocking bradykinin (BK) production and the complement activation, key mediators of episodic AE. Advantages: New target and compositions for the treatment of AE l Novel mechanism of action for blocking the production of BK and the complement activation Applications: Diagnostic and therapeutic applications for hereditary and drug induced AE Intellectual Property Summary: Issued Patent # 8,883,153 Stage of Development: In vitro data is available. Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. Licensing Status: Available for License Additional Information: gC1qR l Angioedema l Vascular leakage l Monoclonal antibodies l Peptides ,
Patent Information:
Technology/Start-up ID: